1181226-02-7
1181226-02-7 结构式
基本信息
4-((3,5-二氯-2-羟基苄基)氨基)-2-羟基苯甲酸
ZL 006
ZL006
4-((3,5-Dichloro-2-hydroxybenzyl)amino)-2-hydroxybenzoic acid
Benzoic acid, 4-[[(3,5-dichloro-2-hydroxyphenyl)methyl]amino]-2-hydroxy-
iGluR,Ionotropic glutamate receptors,ZL006,ZL-006,Inhibitor,inhibit,ZL 006
物理化学性质
| 报价日期 | 产品编号 | 产品名称 | CAS号 | 包装 | 价格 |
| 2024/04/30 | HY-100456 | 化合物ZL006 ZL006 | 1181226-02-7 | 5mg | 700元 |
| 2024/04/30 | HY-100456 | 化合物ZL006 ZL006 | 1181226-02-7 | 10mM * 1mLin DMSO | 770元 |
| 2024/04/30 | HY-100456 | 化合物ZL006 ZL006 | 1181226-02-7 | 10mg | 1000元 |
常见问题列表
ZL006 presents little cytotoxicity, and a growth inhibition of BCECs is not found at low concentration of 0.001, 0.01, 0.1, 1 and 10 μg/mL. The cytotoxicity of T7-P-LPs/ZL006 is significantly enhanced at the concentration of 10 μg/mL. Cellular uptake of ZL006 loads P-LPs and T7-P-LPs after incubation for 0.5 h at the concentrations range from 100 μg/mL to 600 μg/mL in BCECs. ZL006 does not inhibit the nNOS-PDZ/PSD-95-PDZ interaction, or perturb the nNOS β-finger.
Compared with P-LPs/ZL006 and free ZL006, T7-P-LPs/ZL006 exhibits a significant increase of drug accumulation in the brain tissue due to its better brain targeting delivery. Compared with free ZL006, P-LPs/ZL006 and T7-P-LPs/ZL006 exhibit a significant decrease of drug accumulation in the liver and kidney.